New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
HEAVY.AI Announces Availability of Analytics Platform Accelerated by NVIDIA Grace Hopper Superchip
-
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
-
Aetion Appoints CEO and New Executive Chair of the Board
-
Form SCHEDULE 13D/A NEXTNAV INC. Filed by: New Enterprise Associates 14, L.P.
-
FIRE1 Secures $120 Million Financing to Revolutionize Heart Failure Care
-
Senti Biosciences (SNTI) Announces Additional $11.5M of Financing
-
Senti Bio Announces Additional $11.5 Million of Financing
-
Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs
-
Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American -
-
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating NeueHealth, Inc. Buyout
-
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of NeueHealth, Inc. (NEUE)
-
Form SCHEDULE 13D/A NeueHealth, Inc. Filed by: New Enterprise Associates 17, L.P.
-
Wall Street ends higher as Santa rally begins
-
NeueHealth to Be Taken Private by NEA and Consortium of Investors
-
Form SCHEDULE 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
-
Marker Therapeutics (MRKR) Announces $16.1 Million Private Placement
-
Marker Therapeutics Announces $16.1 Million Private Placement
-
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
-
Form SC 13D/A Senti Biosciences, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Senti Biosciences (SNTI) Announces Oversubscribed $37.6 Million Private Placement Equity Financing
-
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
-
Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson's Disease
-
SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension
-
Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing
-
Tuya Inc. (TUYA) Announces Anchor Investment by 65 Equity Partners
-
Tuya Announces Anchor Investment by 65 Equity Partners
-
Emulate Energy and Smartcar Partner to Drive EV Utilization as Distributed Energy Resources
-
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A CVRx, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Form 144 CVRx, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 8A L P
-
Form 144 CVRx, Inc. Filed by: NEW ENTERPRISE ASSOCIATES VIII L P
-
Form SC 13G/A Tuya Inc. Filed by: New Enterprise Associates 14, L.P.
-
Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development
-
US autonomous truck startup Outrider raises $62 million to scale up
-
Outrider Closes $62 Million Series D Financing to Drive Growth of Yard Automation
-
Form SC 13D/A Inventiva S.A. Filed by: New Enterprise Associates 17, L.P.
-
Global Health Exhibition Opens its Doors Tomorrow to Record-Breaking 100,000+ Attendees to World's Premier Healthcare Transformation Event
-
Stride Annual Open Enrollment Research Reveals 73% of ACA Buyers Will Not Compare Plans Heading into 2025, Despite Anticipated Premium Increases
-
Inventiva SA (IVA) PT Lowered to $13 at H.C. Wainwright
-
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
-
Form SC 13D/A OnKure Therapeutics, Filed by: New Enterprise Associates 15, L.P.
-
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
-
ReCode Announces Two Key Additions to Scientific Advisory Board
-
Revelation Partners Deepens Healthcare Expertise with Two New Hires
-
Stride Publishes Study Revealing Financial Challenges Faced by Millions of Independent Workers
-
Lyft and Smartcar Partner to Tackle the Top Pain Point for EV Drivers — Range Anxiety
-
Form SC 13D MBX Biosciences, Inc. Filed by: New Enterprise Associates 17, L.P.
-
Functional Finance Secures $20M Series A Funding Led by Walkabout Ventures
-
Form 4 MBX Biosciences, Inc. For: Sep 16 Filed by: New Enterprise Associates 17, L.P.

